Valeant to buy private dental company for $312 million Fri Jun 15, 2012 11:56am EDT (Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc will buy privately held drugmaker OraPharma for about $312 million, to enter the dental market. The company, which has been on a buying spree across various geographies since Michael Pearson took over as its chief executive four years ago, said it will also pay $114 million in potential contingent payments based on certain milestones. The deal, which is expected to close in June, will add to Valeant's earnings in 2012, the company said in a statement. OraPharma is owned by private equity firm Water Street Healthcare Partners. The company makes Arestin, a locally administered antibiotic for the treatment of periodontitis - an infection of the ligaments and bones that support the teeth. As of March 31, OraPharma's twelve month net revenue was about $95 million. Reporting by Aftab Ahmed in Bangalore; Editing by Supriya Kurane